Therapeutically, strategies aiming to restore CASP1 activity, deplete or inhibit FOXP3+ Tregs, or target PDIA3-related antigen presentation defects could enhance immune surveillance and improve responsiveness to immunotherapy in multiple cancer types. This evidence concerns the gene PDIA3 and cancer.